参考文献: [1] Fizazi K, Tran N, Fein LE, et al;LATITUDE Investigators. Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer[J]. N Engl J Med. 2017;377(4):352-360. [2] EAU/ESTRO/ESUR...
[2] Men with metastatic prostate cancer live longer thanks to new drugs, study finds.Retrieved Jun 23,2023,from https://medicalxpress.com/news/2023-10-men-metastatic-prostate-cancer-longer.html
6. Alicia K. Morgans, et al. Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS. ASCO 2022. Poster 228. 7. Wenzel M, et al. Prostate Cancer Prostatic Dis. 2021 May 30. PP-NUB-CN-0215-1 仅供与医疗卫...
8.DAVIS I D, MARTIN A J, STOCKLER M R, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J]. N Engl J Med, 2019, 381(2): 121-31. 9. FIZAZI K, FOULON S, CARLES J, et ...
[3] 1.Chi K M, et al. Final analysis results from TITAN: a phase 3 study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy. J Clin Oncol 39, 2021 (suppl 6; abstr 11). ...
[2]Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021 Jul 10;39(20):2294-2303. ...
[3] Smith MR, Yu MK, Small EJ. Apalutamide and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:2542. [4] Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235–46 ...
[6] Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN:Outcomes in patients (pts) with low- and high-risk disease. Mustafa O, et al., 2020 ASCO GU. Abstract 87. [7] Chi K N, Chowdhury S, Bjartell A et al. Final analysis results from TITAN: A...
4. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 . 5. Maha H. A. Hussain, et al. 2023 ASCO GU Oral 15. 6. ESMO 2023: Abstract 1784P. ...
4. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 . 5. Maha H. A. Hussain, et al. 2023 ASCO GU Oral 15. 6. ESMO 2023: Abstract 1784P. ...